Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

[1]  Sashank Prasad,et al.  Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature , 2015, Ocular immunology and inflammation.

[2]  A. Faje.  Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights , 2016, Pituitary.

[3]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[4]  A. Razak,et al.  A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Amitabh Srivastava,et al.  Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases , 2015, The American journal of surgical pathology.

[6]  F. Hodi,et al.  Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. , 2015, The New England journal of medicine.

[7]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[8]  M. McDonagh,et al.  Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop , 2015, Annals of Internal Medicine.

[9]  D. Schadendorf,et al.  Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. , 2015 .

[10]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[11]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[12]  David C. Smith,et al.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Orlov,et al.  Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. , 2015, The Journal of clinical endocrinology and metabolism.

[14]  G. Mayer,et al.  Frequency, risk factors and prophylaxis of infection in ANCA‐associated vasculitis , 2015, European journal of clinical investigation.

[15]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[16]  Y. H. Lee,et al.  Meta-analysis of genetic polymorphisms in programmed cell death 1 , 2015, Zeitschrift für Rheumatologie.

[17]  B. Xiang,et al.  The association of cytotoxic T-lymphocyte antigen-4 + 49A/G and CT60 polymorphisms with type 1 diabetes and latent autoimmune diabetes in Chinese adults , 2015, Journal of Endocrinological Investigation.

[18]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[19]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[20]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[21]  J. B. Oliveira,et al.  Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4 , 2014, Science.

[22]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[23]  B. Dréno,et al.  Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. , 2014, Journal of immunotherapy.

[24]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[25]  Antoni Ribas,et al.  Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients , 2014, Science Translational Medicine.

[26]  J. Wolchok,et al.  Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody , 2014, Science Translational Medicine.

[27]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Tummala,et al.  Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. , 2014, Neuro-oncology.

[29]  C. Robert,et al.  Kidney injuries related to ipilimumab , 2014, Investigational New Drugs.

[30]  J. Wolchok,et al.  Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. , 2014, Endocrine-related cancer.

[31]  D. Todd,et al.  Drug‐Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA‐4 , 2014, Arthritis & rheumatology.

[32]  L. Gordon,et al.  Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Y. Lee,et al.  Association between CTLA-4 polymorphisms and susceptibility to Celiac disease: a meta-analysis. , 2013, Human immunology.

[34]  P. Darcy,et al.  Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy , 2013, Oncoimmunology.

[35]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[36]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[37]  R. Dummer,et al.  Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab , 2013, Cancer.

[38]  C. Blank,et al.  Neurological immune-related adverse events of ipilimumab , 2013, Practical Neurology.

[39]  D. Stover,et al.  Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. , 2013, Chest.

[40]  S. Tirumani,et al.  Ipilimumab associated hepatitis: imaging and clinicopathologic findings , 2013, Investigational New Drugs.

[41]  A. Hauschild,et al.  Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  C. Berking,et al.  The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network , 2013, PloS one.

[43]  Colin D Johnson,et al.  Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus , 2012, Gut.

[44]  K. O'Byrne,et al.  Ipilimumab-induced immune-related renal failure--a case report. , 2012, Anticancer research.

[45]  S. Andrews,et al.  Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma , 2012, Cancer management and research.

[46]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[48]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[49]  S. Peters,et al.  Pulmonary sarcoid-like granulomatosis induced by ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Dieci,et al.  Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[52]  C. Mateus,et al.  Hemophilia A induced by ipilimumab. , 2011, The New England journal of medicine.

[53]  B. Neyns,et al.  Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[55]  J. Stone,et al.  Treatment of primary Sjögren syndrome: a systematic review. , 2010, JAMA.

[56]  T. Gajewski,et al.  Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy , 2010, Cancer journal.

[57]  J. Wolchok,et al.  Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting , 2010, Cancer.

[58]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[59]  B. Knebelmann,et al.  Anti-CTLA4 antibody-induced lupus nephritis. , 2009, The New England journal of medicine.

[60]  Z. Layrisse,et al.  Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases. , 2009, Human immunology.

[61]  E. Waller,et al.  Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). , 2009, Journal of immunotherapy.

[62]  M. Upton,et al.  Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. , 2009, Journal of immunotherapy.

[63]  M. Tzardi,et al.  Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[64]  J. Barkin,et al.  Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab , 2009, Digestive Diseases and Sciences.

[65]  T. Gajewski,et al.  Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma , 2009, Cancer Immunology, Immunotherapy.

[66]  M. Maio,et al.  Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases , 2009, Cancer Immunology, Immunotherapy.

[67]  L. Thomas,et al.  Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient , 2008, Dermatology.

[68]  S. Rosenberg,et al.  Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma , 2006, Journal of immunotherapy.

[69]  A. Feldman,et al.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  B. Comin-Anduix,et al.  Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  A. Zhernakova,et al.  CTLA4 is differentially associated with autoimmune diseases in the Dutch population , 2005, Human Genetics.

[72]  S. Rosenberg,et al.  Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. , 2004, Journal of immunotherapy.

[73]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[74]  R. Jonsson,et al.  A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans , 2002, Nature Genetics.

[75]  J. Pandey,et al.  CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region , 2002, Human Genetics.

[76]  S. Pearce,et al.  An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. , 2002, Rheumatology.

[77]  R. Williams,et al.  Azathioprine for long-term maintenance of remission in autoimmune hepatitis. , 1995, The New England journal of medicine.